| Description | Hexahydrocurcumin is a selective, orally active COX-2 inhibitor and inactive against COX-1. |
| In vitro | Hexahydrocurcumin (0-25 μM; 24-48小时; HT-29细胞)处理显著降低HT-29结肠癌细胞的活性，其作用呈时间和浓度依赖性，24小时和48小时暴露下的IC50值分别为77.05和56.95。联合使用Hexahydrocurcumin (0-25 μM; 24-48小时; HT-29细胞)和5-氟尿嘧啶(5-FU; 5 μM)显著降低了COX-2的表达，而COX-1的水平未发生变化[1]。Hexahydrocurcumin (7-14 μM; 24小时)能够浓度依赖性地减轻内毒素LPS诱导的小鼠巨噬细胞(RAW 264.7)中前列腺素E2 (PGE2)的增加[2]。 |
| In vivo | 在结肠癌大鼠模型中，Hexahydrocurcumin（50 mg/kg；口服给药；每日一次；持续16周；雄性Wistar大鼠）的治疗显著降低了异常隐窝灶的数量。Hexahydrocurcumin还显著降低了COX-2蛋白的表达[3]。 |
| Cell experiments | Cell Line: HT-29 cells. Concentration: 0 μM, 5 μM, 10 μM, 25 μM. Incubation Time: 24 hours or 48 hours [1] |
| Animal experiments | Animal Model: Male Wistar rats (100-120 g) injected with dimethylhydrazine (DMH). Dosage: 50 mg/kg. Administration: Oral administration; daily; for 16 weeks [3] |
| molecular weight | 374.43 |
| Molecular formula | C21H26O6 |
| CAS | 36062-05-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (120.19 mM), Sonication is recommended. |
| References | 1. Srimuangwong K, et al. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol. 2012 May 21;18(19):2383-9. 2. Li F, et al. In vitro antioxidant and anti-inflammatory activities of 1-dehydro-[6]-gingerdione, 6-shogaol, 6-dehydroshogaol and hexahydrocurcumin. Food Chem. 2012 Nov 15;135(2):332-7. 3. Srimuangwong K, et al. Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats. World J Gastroenterol. 2012 Dec 21;18(47):6951-9. |